Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Geriatrics Reports
Published in: Current Geriatrics Reports 4/2017

01-12-2017 | Hematology and Oncology (GR Williams, Section Editor)

Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia

Authors: Susan Storey, Tamryn Fowler Gray, Ashley Leak Bryant

Published in: Current Geriatrics Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

The purpose of this study is to describe the pathology, impact of comorbidities, functional limitations, symptoms, and quality of life (QOL) related to treatment of acute myeloid leukemia (AML) in older adults.

Recent Findings

AML is a rare aggressive hematologic disease that occurs most often in older adults. The prognosis for older patients with AML is markedly worse due to genetic mutations and patient characteristics such as comorbidities and functional limitations. Patient characteristics may influence treatment decisions, as well as impact symptoms, functional ability, health-related outcomes, and QOL.

Summary

As the population continues to age, the number of people diagnosed with AML is expected to increase. Better management of comorbidities is imperative to improving QOL and other treatment-related outcomes. Prospective, longitudinal, and multi-site studies are warranted to further understand the interaction between these characteristics on symptoms, outcomes, and QOL.
Literature
1.
•• Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leukemia research reports. 2016;6:1–7. This study provides evidence for how the most frail and oldest among the oldest will have the least net benefit from chemotherapy or hematopoietic transplantation, even if they receive the best available treatment, while the fittest and youngest patients will benefit most. CrossRefPubMedPubMedCentral
2.
Krug U, Buchner T, Berdel WE, Muller-Tidow C. The treatment of elderly patients with acute myeloid leukemia. Deutsches Arzteblatt international. 2011;108(51–52):863–70.PubMedPubMedCentral
3.
4.
5.
Klepin HD, Danhauer SC, Tooze JA, Stott K, Daley K, Vishnevsky T, et al. Exercise for older adult inpatients with acute myelogenous leukemia: a pilot study. Journal of geriatric oncology. 2011;2(1):11–7.CrossRefPubMedPubMedCentral
6.
•• Sanford D, Ravandi F. Management of newly diagnosed acute myeloid leukemia in the elderly: current strategies and future directions. Drugs Aging. 2015;32(12):983–97. This study suggests the importance of assessing fitness for intensive induction therapy in older adults using a standardized approach that incorporates performance status, burden of comorbidities, and patient preferences, as well as assessment for enrollment in clinical trials when available and feasible in the management of AML in older adults. CrossRefPubMed
7.
8.
Vey N. Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress? Interdiscip Top Gerontol. 2013;38:73–84.CrossRefPubMed
9.
Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammaging. Longevity & healthspan. 2013;2(1):8.CrossRef
10.
Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. Curr Opin Immunol. 2014;29:23–8.CrossRefPubMed
11.
•• Klepin HD. Elderly acute myeloid leukemia: assessing risk. Current hematologic malignancy reports. 2015;10(2):118–25. Physiologic changes of aging that decrease treatment tolerance also influence outcomes and vary among patients of the same chronologic age so improving risk prediction for older adults is important in improving the chances that older adults will tolerate and benefit from therapies. CrossRefPubMedPubMedCentral
12.
• Wang ES. Treating acute myeloid leukemia in older adults. Hematology American Society of Hematology Education Program. 2014;2014(1):14–20. Treatment of older adults with AML is challenging because there is no consensus regarding optimal therapy. PubMed
13.
Fulop T, et al. Aging, frailty and age-related diseases. Biogerontology. 11(5):547–63.
14.
15.
Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;96(5):696–702.CrossRefPubMedPubMedCentral
16.
Preussler JM, Meyer CL, Mau LW, Majhail NS, Denzen EM, Edsall KC, et al. Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(6):1021–8.CrossRefPubMed
17.
18.
•• Storey S, Von Ah D. Prevalence and impact of hyperglycemia on hospitalized leukemia patients. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2015;19(1):13–7. The findings from this study provide preliminary evidence demonstrating hyperglycemia in the leukemia patient is common and has detrimental effects on clinical outcomes; specifically patients with hyperglycemia were 1.6 times more likely ( p < 0.01) to experience neutropenia than those without hyperglycemia, and hospital length of stay was significantly longer in patients with hyperglycemia (2 versus 15 days; p < 0.001). CrossRef
19.
•• Storey S, Von Ah D. Impact of hyperglycemia and age on outcomes in patients with acute myeloid leukemia. Oncol Nurs Forum. 2016;43(5):595–601. This study provides preliminary evidence that hyperglycemia may have harmful consequences during initial induction for AML, particularly among those ≥ 65; these patients had 5.6 ( p = .022) times greater risk of infection than those < 65; more days of neutropenia were found but not statistically significant. CrossRefPubMed
20.
Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(24):2541–52.CrossRef
21.
Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, Coso D, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007;109(7):1376–83.CrossRefPubMed
22.
• Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma. 2014;55(5):979–87. This review highlights the challenges of treating older adults with AML (including combination of less toxic agents and other non-toxic therapies, novel targeted agents, resource utilization and allocation, and identifying suitability among patients for aggressive treatment therapies) and the divergent views between physicians and patients about determining fitness for intensive chemotherapy. CrossRefPubMed
23.
•• Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, et al. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. Hematology (Amsterdam, Netherlands). 2012;17(2):53–8. The aim of this study was to detemine which factors are associated with poor prognosis in patients with AML of all ages, and results found that in patients aged 55 years, the most significant predictor of poor overall survival and early death was comorbidity.
24.
25.
Thomas X, Lejeune C. Blinatumomab in acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2016;16(3):251–3.CrossRefPubMed
26.
•• Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma—a Swedish population-based study. BMC Cancer. 2015;15:850. Comorbidity increases overall mortality in patients diagnosed with hematological malignancies. The impact of comorbidity on cancer-specific mortality, taking competing risks into account, has not been evaluated. CrossRefPubMedPubMedCentral
27.
Ostgard LS, Norgaard JM, Sengelov H, Severinsen M, Friis LS, Marcher CW, et al. Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia. 2015;29(3):548–55.CrossRefPubMed
28.
Tawfik B, et al. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). Journal of geriatric oncology. 2016;7(1):24–31.CrossRefPubMed
29.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207–21.CrossRefPubMed
30.
Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23(6):967–81.CrossRefPubMedPubMedCentral
31.
Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H, et al. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619–32.CrossRefPubMed
32.
• Vissers PA, Falzon L, van de Poll-Franse LV, Pouwer F, Thong MS. The impact of having both cancer and diabetes on patient-reported outcomes: a systematic review and directions for future research. Journal of cancer survivorship : research and practice. 2016;10(2):406–15. This systematic review demonstrates that the presence of both cancer and diabetes resulted in worse patient reported outcomes (heath-related quality life), compared to having either one of the diseases independently, and highlighting the need for more studies. CrossRef
33.
Association AD. Standards of medical care in diabetes. Diabetes Care. 2017;40(1):S1–132.
34.
Umpierrez GE, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2012;97(1):16–38.CrossRef
35.
•• Brady VJ, Grimes D, Armstrong T, LoBiondo-Wood G. Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review. Oncol Nurs Forum. 2014;41(6):E355–65. This review of literature noted the occurrence of hyperglycemia in hospitalized patients with cancer irrespective of whether patients have a prior history of diabetes. CrossRefPubMed
36.
Hammer MJ, Motzer SA, Voss JG, Berry DL. Glycemic control among older adult hematopoietic cell transplant recipients. J Gerontol Nurs. 2010;36(2):40–50.CrossRefPubMed
37.
•• Storey S, Diane Von A. Impact of malglycemia on clinical outcomes in hospitalized patients with cancer: a review of the literature. Oncol Nurs Forum. 2012;39(5):458–65. This review of literature examined the findings of 11 research articles that reported the impact of malglycemia (mostly hyperglycemia) on the various outcomes (infection, mortality, survival, toxicity and length of stay) among patients with heterogeneous types of cancer. CrossRefPubMed
38.
• Olausson JM, Hammer MJ, Brady V. The impact of hyperglycemia on hematopoietic cell transplantation outcomes: an integrative review. Oncol Nurs Forum. 2014;41(5):E302–12. This integrative review of published literature found associations between hyperglycemia and infection, time to engraftment, development of acute graft-versus-host disease, length of stay, and overall survival among HCT patients. CrossRefPubMed
39.
Matias CN, Lima V, Teixeira HM, Souto FR, Magalhaes V. Hyperglycemia increases the complicated infection and mortality rates during induction therapy in adult acute leukemia patients. Rev Bras Hematol Hemoter. 2013;35(1):39–43.CrossRefPubMedCentral
40.
Ali NA, O'Brien JM Jr, Blum W, Byrd JC, Klisovic RB, Marcucci G, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007;110(1):96–102.CrossRefPubMed
41.
Storey S, Von Ah D, Hammer MJ. Measurement of hyperglycemia and impact on health outcomes in people with cancer: challenges and opportunities. Oncol Nurs Forum. 2017;44(4):E141–e51.CrossRefPubMed
42.
Pettit K, Odenike O. Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies. Front Oncol. 2015; 5:280.
43.
Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208–16.CrossRefPubMedPubMedCentral
44.
Hershey DS, Given B, Given C, Corser W, von Eye A. Predictors of diabetes self-management in older adults receiving chemotherapy. Cancer Nurs. 2014;37(2):97–105.CrossRefPubMed
45.
Alibhai SM, O’Neill S, Fisher-Schlombs K, Breunis H, Brandwein JM, Timilshina N, et al. A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Leuk Res. 2012;36(10):1255–61.CrossRefPubMedPubMedCentral
46.
Leak Bryant A, Lee Walton A, Shaw-Kokot J, Mayer DK, Reeve BB. Patient-reported symptoms and quality of life in adults with acute leukemia: a systematic review. Oncol Nurs Forum. 2015;42(2):E91–E101.CrossRefPubMed
47.
Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–9.CrossRefPubMedPubMedCentral
48.
49.
Mariano C, Williams G, Deal A, Alston S, Bryant AL, Jolly T, et al. Geriatric assessment of older adults with cancer during unplanned hospitalizations: an opportunity in disguise. Oncologist. 2015;20(7):767–72.CrossRefPubMedPubMedCentral
50.
Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. JAMA. 2004;292(17):2115–24.CrossRefPubMed
51.
Chuang KH, Covinsky KE, Sands LP, Fortinsky RH, Palmer RM, Landefeld CS. Diagnosis-related group-adjusted hospital costs are higher in older medical patients with lower functional status. J Am Geriatr Soc. 2003;51(12):1729–34.CrossRefPubMed
52.
Law M, Steinwender S, Leclair L. Occupation, health and well-being. Can J Occup Ther. 1988;65(2):81–91.CrossRef
53.
Law M. Participation in the occupations of everyday life. The American journal of occupational therapy : official publication of the American Occupational Therapy Association. 2002;56(6):640–9.CrossRef
54.
Vessby K, Kjellberg A. Participation in occupational therapy research: a literature review. Br J Occup Ther. 2010;73(7):319–26.CrossRef
55.
Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.CrossRefPubMed
56.
Mustian KM, Sprod LK, Palesh OG, Peppone LJ, Janelsins MC, Mohile SG, et al. Exercise for the management of side effects and quality of life among cancer survivors. Curr Sports Med Rep. 2009;8(6):325–30.CrossRefPubMedPubMedCentral
57.
Sprod LK, Mohile SG, Demark-Wahnefried W, Janelsins MC, Peppone LJ, Morrow GR, et al. Exercise and cancer treatment symptoms in 408 newly diagnosed older cancer patients. Journal of geriatric oncology. 2012;3(2):90–7.CrossRefPubMedPubMedCentral
58.
Battaglini CL, Hackney AC, Garcia R, Groff D, Evans E, Shea T. The effects of an exercise program in leukemia patients. Integrative cancer therapies. 2009;8(2):130–8.CrossRefPubMed
59.
Bryant AL, Deal AM, Battaglini CL, Phillips B, Pergolotti M, Coffman E, Foster M, Wood WA, Bailey C, Hackney AC, Mayer, DK,Muss H, Reeve BB. The effects of exercise on patientreported outcomes and performance-based physical function in adults with acute leukemia undergoing induction therapy. Integrative Cancer Therapies. 2017. https://​doi.​org/​10.​1177/​1534735417699881​.
60.
Chang PH, Lai YH, Shun SC, Lin LY, Chen ML, Yang Y, et al. Effects of a walking intervention on fatigue-related experiences of hospitalized acute myelogenous leukemia patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manag. 2008;35(5):524–34.CrossRef
61.
Jarden M, Møller T, Kjeldsen L, Birgens H, Christensen JF, Christensen KB, et al. Patient activation through counseling and exercise–acute leukemia (PACE-AL)—a randomized controlled trial. BMC Cancer. 2013;13(1):446.CrossRefPubMedPubMedCentral
62.
Rogers BB. Advances in the management of acute myeloid leukemia in older adult patients. Oncol Nurs Forum. 2010;37(3):E168–79.CrossRefPubMed
63.
El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, et al. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015;121(16):2840–8.CrossRefPubMedPubMedCentral
64.
Nazha A, Khoury JD, Verstovsek S, Daver N. Second line therapies in polycythemia vera: what is the optimal strategy after hydroxyurea failure? Crit Rev Oncol Hematol. 2016;105:112–7.CrossRefPubMed
65.
Taylor LK, et al. Potential prevention of small for gestational age in Australia: a population-based linkage study. BMC pregnancy and childbirth. 2013;13(1):210.CrossRefPubMedPubMedCentral
66.
Puchalski CM, et al. Spirituality and health: the development of a field. Acad Med. 2014;89(1):10–6.CrossRefPubMed
67.
Ghodraty-Jabloo V, et al. Keep your mind off negative things: coping with long-term effects of acute myeloid leukemia (AML). Support Care Cancer. 2016;24:2035–45.CrossRefPubMed
68.
69.
Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–24.CrossRefPubMed
70.
Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908–15.CrossRefPubMed
71.
Hamaker ME, Stauder R, van Munster BC. Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry. Oncologist. 2014;19(10):1069–75.CrossRefPubMedPubMedCentral
72.
73.
74.
Siu LL. Clinical trials in the elderly—a concept comes of age. N Engl J Med. 2007;356(15):1575–6.CrossRefPubMed
Metadata
Title
Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia
Authors
Susan Storey
Tamryn Fowler Gray
Ashley Leak Bryant
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Geriatrics Reports / Issue 4/2017
Electronic ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-017-0227-8

Other articles of this Issue 4/2017

Current Geriatrics Reports 4/2017 Go to the issue

Hematology and Oncology (GR Williams, Section Editor)

Polypharmacy in Older Adults with Cancer: Evaluating Polypharmacy as Part of the Geriatric Assessment

Cardiovascular Disease in the Elderly (M Chen, Section Editor)

Care of the Elderly Patient with Infective Endocarditis

Hematology and Oncology (GR Williams, Section Editor)

Rehabilitation Strategies in Older Adult Oncology Patients: a Focus on Occupational and Physical Therapy

Hematology and Oncology (GR Williams, Section Editor)

Assessing Frailty and Vulnerability in Older Adults with Cancer

Cardiovascular Disease in the Elderly (M Chen, Section Editor)

Implantable Cardioverter-Defibrillator Implantation, Continuation, and Deactivation in Elderly Patients

Hematology and Oncology (GR Williams, Section Editor)

Sarcopenia in Oncology or Gerontology: What Is the Difference?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits